Table 2

Baseline CRP levels in the different studies

Study acronymStudy groupBaseline CRP (mg/L)CRP inclusion criteria
IMPACT 211InfliximabMean 19SD 24Either CRP ≥15 mg/L and/or morning stiffness ≥45 min
PlaceboMean 23SD 34
GO-REVEAL13Golimumab 50 mgMean 13SD 16/
Golimumab 100 mgMean 14SD 18
PlaceboMean 13SD 16
ADEPT14AdalimumabMean 14SD 21/
PlaceboMean 14SD 17
SPIRIT-P116AdalimumabMean 13.2SD 19.1Either ≥1 PsA-related hand or foot joint erosion on centrally read X-rays or CRP >6 mg/L
Ixekizumab every 2 weeksMean 15.1SD 25.9
Ixekizumab every 4 weeksMean 12.8SD 16.4
PlaceboMean 15.1SD 23.6
OPAL BROADEN17Tofacitinib 5 mgMedian 4.8Range 0.2–115/
Tofacitinib 10 mgMedian 5.1Range 0.2–92.9
AdalimumabMedian 4.3Range 0.2–131.0
PlaceboMedian 5.0Range 0.2–113.0
RAPID-PsA19Certolizumab every 2 weeksMedian 7.0Min 0.2 – Max 238.0Either ESR ≥28 mm/hour or CRP >7.9 mg/L
Certolizumab every 4 weeksMedian 8.7Min 0.1 – Max 131.0
PSUMMIT 126Ustekinumab 45 mgMedian 10.0IQR 5.9–21.1CRP ≥3 mg/L
Ustekinumab 90 mgMedian 12.3IQR 6.5–21.7
PlaceboMedian 9.6IQR 6.0–18.6
PSUMMIT 228Ustekinumab 45 mgMedian 13.0IQR 4.5–36.3Screening CRP ≥6 mg/L, modified to ≥3 mg/L after study start
Ustekinumab 90 mgMedian 10.1IQR 4.8–19.8
PlaceboMedian 8.5IQR 4.6–22.0
DISCOVER 129Guselkumab every 4 weeksMedian 6IQR 3–13CRP ≥3 mg/L
Guselkumab every 8 weeksMedian 7IQR 4–19
PlaceboMedian 8IQR 3–15
DISCOVER 230Guselkumab every 4 weeksMedian 12IQR 6–23CRP ≥6 mg/L
Guselkumab every 8 weeksMedian 13IQR 7–25
PlaceboMedian 12IQR 2–26
ASTRAEA31AbataceptMean 14.0SD 20.9/
PlaceboMean 14.3SD 30.3
OPAL BEYOND33Tofacitinib 5 mgMedian 5.7Range 0.2–126.0/
Tofacitinib 10 mgMedian 4.9Range 0.2–163.0
PlaceboMedian 4.4Range 0.2–164.0
PALACE 134Apremilast 20 mgMean 9.0SD 14.09/
Apremilast 30 mgMean 8.4SD 10.24
PlaceboMean 11SD 14.36
PALACE 336Apremilast 20 mgMean 9.7SD 15.1/
Apremilast 30 mgMean 11.5SD 18.8
PlaceboMean 10SD 13.5
PALACE 437Apremilast 20 mgMean 9SD 11/
Apremilast 30 mgMean 8SD 11
PlaceboMean 11SD 27
ACTIVE38Apremilast 30 mgMean 14.4SD 16CRP ≥2 mg/L
PlaceboMean 12.5SD16
  • CRP, C reactive protein; ESR, erythrocyte sedimentation rate; max, maximum; PsA, psoriatic arthritis.